Thermo Fisher Scientific Deal Expands Possibilities for Exosome Dx Business, Bio-Techne CEO Says
The deal with Thermo Fisher is for the development of Bio-Techne's second test in its Exosome Diagnostics portfolio, a multigene assay for kidney transplant rejection.
Bio-Techne Obtains Reimbursement Contract With Humana for Exosome Diagnostics Prostate Biopsy Test
Bio-Techne's CEO said the coverage decision will expand access to its EPI test and enable additional men to better decide whether to proceed with a prostate biopsy.
Qiagen, Exosome Dx Building Urine-Based Digital PCR Workflow for FGFR Mutations in Bladder Cancer
The firms will present a clinical comparison study using the workflow to detect FGFR mutations in 50 urothelial cancer patients later this year.
Bio-Techne Bets Clinical Utility Study Data Will Sway Payors to Cover Prostate Cancer Risk Test
The Minneapolis-based firm believes the assay can successfully serve as a clinical indicator for patients at risk of developing high-grade prostate cancer (HGPC), thereby improving prostate cancer management.
Bio-Techne Receives Medicare Coverage for Prostate Cancer Test
The decision, which enables Medicare reimbursement, is effective for tests administered on or after Dec. 1.